Taltz ® (ixekizumab)

Taltz® (ixekizumab): Were Hepatitis B Events reported in Clinical Trials?

Information about hepatitis B events with ixekizumab treatment in psoriasis, psoriatic arthritis, and axial spondyloarthritis clinical trials is provided.


Ixekizumab Label Information Related to Infections

Ixekizumab is contraindicated in patients with clinically important active infections (e.g. active tuberculosis).1

Treatment with ixekizumab is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections.1

Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection. 1

Patients should be instructed to seek medical advice if signs or symptoms suggestive of an infection occur.1

If an infection develops,

  • patients should be carefully monitored and 
  • ixekizumab discontinued if
    • the patient is not responding to standard therapy or if
    • the infection becomes serious.1

Ixekizumab should not be resumed until the infection resolves.1

Hepatitis B is not listed as adverse reaction in the Taltz summary of product characteristics.1

Clinical Trial Exclusion Criteria

Patients who had tested positive for hepatitis B, or who had evidence of acute or chronic hepatitis B infection, were excluded from the pivotal ixekizumab clinical trials.2,3

Hepatitis B Events in Clinical Trials

Analyses of hepatic-related AEs did not demonstrate clinically important adverse effects related to ixekizumab treatment in patients with PsO or PsA. Longer-term exposure with ixekizumab was not associated with an increased risk of hepatic-related AEs. There were no clinically meaningful differences in the frequency of hepatic-related TEAEs (narrow terms) across treatment groups in the axSpA clinical studies.3


Among all ixekizumab exposures in adult and pediatric PsO trials (N=6645; PY=17,902), as of March 2020, 1 patient had a positive hepatitis B virus DNA test.3

Psoriatic Arthritis

Among all ixekizumab exposures in PsA (data from SPIRIT-P1, -P2, -P3, and SPIRIT-H2H; N=1401; PY=2247.7), as of March 2020, 1 patient with a history of hepatitis B virus had a positive hepatitis B virus DNA test. Although the result was below the level of quantification, the patient discontinued from the study per protocol. Subsequent hepatitis B virus DNA tests for the patient were negative.3,4

Axial Spondyloarthritis

Among all ixekizumab exposures in axSpA (including AS/r-axSpA and nr-axSpA trials) (N=932; 1792.2 PYs), as of March 2020, 1 patient had a positive hepatitis B virus DNA test.3


1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

2Gordon KB, Blauvelt A, Papp KA, et al; UNCOVER-1, UNCOVER-2, and UNCOVER-3 Study Groups. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711

3Data on file, Eli Lilly and Company and/or one of its subsidiaries.

4Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367-378. http://dx.doi.org/doi:10.1002/acr.23738


AE = adverse event

AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis

axSpA = axial spondyloarthritis

nr-axSpA = nonradiographic axial spondyloarthritis

PsA = psoriatic arthritis

PsO = psoriasis

PY = patient-years

TEAE = treatment-emergent adverse event

Date of Last Review: August 06, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request